Catalyst Pharmaceuticals Total Assets 2010-2025 | CPRX

Catalyst Pharmaceuticals total assets from 2010 to 2025. Total assets can be defined as the sum of all assets on a company's balance sheet.
Catalyst Pharmaceuticals Annual Total Assets
(Millions of US $)
2024 $851
2023 $470
2022 $376
2021 $238
2020 $192
2019 $112
2018 $60
2017 $85
2016 $42
2015 $60
2014 $44
2013 $25
2012 $17
2011 $6
2010 $6
2009 $8
Catalyst Pharmaceuticals Quarterly Total Assets
(Millions of US $)
2025-03-31 $909
2024-12-31 $851
2024-09-30 $772
2024-06-30 $706
2024-03-31 $647
2023-12-31 $470
2023-09-30 $413
2023-06-30 $444
2023-03-31 $407
2022-12-31 $376
2022-09-30 $333
2022-06-30 $267
2022-03-31 $247
2021-12-31 $238
2021-09-30 $223
2021-06-30 $209
2021-03-31 $197
2020-12-31 $192
2020-09-30 $175
2020-06-30 $131
2020-03-31 $118
2019-12-31 $112
2019-09-30 $97
2019-06-30 $78
2019-03-31 $61
2018-12-31 $60
2018-09-30 $68
2018-06-30 $74
2018-03-31 $79
2017-12-31 $85
2017-09-30 $35
2017-06-30 $36
2017-03-31 $38
2016-12-31 $42
2016-09-30 $45
2016-06-30 $49
2016-03-31 $54
2015-12-31 $60
2015-09-30 $65
2015-06-30 $68
2015-03-31 $76
2014-12-31 $44
2014-09-30 $46
2014-06-30 $46
2014-03-31 $22
2013-12-31 $25
2013-09-30 $29
2013-06-30 $13
2013-03-31 $14
2012-12-31 $17
2012-09-30 $12
2012-06-30 $8
2012-03-31 $5
2011-12-31 $6
2011-09-30 $4
2011-06-30 $6
2011-03-31 $7
2010-12-31 $6
2010-09-30 $6
2010-06-30 $6
2010-03-31 $7
2009-12-31 $8
2009-09-30 $5
2009-06-30 $6
2009-03-31 $9
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $3.045B $0.492B
Catalyst Pharmaceuticals, Inc. is a development-stage biopharmaceutical company focused on the development and commercialization of therapies targeting rare neurological diseases and disorders, like Lambert-Eaton Myasthenic Syndrome (LEMS), epilepsy and Tourette syndrome. Catalyst in-licensed rights to Firdapse (for treating LEMS) from BioMarin Pharmaceutical Inc. for its development and commercialization in the U.S. Firdapse is currently approved in the European Union and in the U.S. for treating of LEMS in adults. The company also plans to file a supplemental new drug application for Firdapse to treat pediatric patients with LEMS.?The company is also strengthening the commercial portfolio of Firdapse. It has already received multiple patents that cover the treatment of all amifampridine metabolizer types within the LEMS patient population.?Apart from Firdapse, the company is working on a generic version of Lundbeck's Sabril, CPP-109, for the treatment of infantile spasms and complex partial seizures.
Stock Name Country Market Cap PE Ratio
Chugai Pharmaceutical (CHGCY) Japan $85.830B 32.20
Zoetis (ZTS) United States $75.075B 28.01
Daiichi Sankyo, - (DSNKY) Japan $50.952B 25.92
Takeda Pharmaceutical (TAK) Japan $47.824B 9.51
Sandoz Group AG (SDZNY) Switzerland $22.282B 0.00
Merck (MKKGY) Germany $17.034B 12.48
United Therapeutics (UTHR) United States $14.382B 12.72
Shionogi (SGIOY) Japan $14.036B 14.06
Summit Therapeutics (SMMT) United States $13.528B 0.00
Neurocrine Biosciences (NBIX) United States $12.175B 41.70
IPSEN (IPSEY) France $9.924B 0.00
Orion OYJ (ORINY) Finland $9.462B 25.59
Corcept Therapeutics (CORT) United States $8.225B 66.86
Stevanato Group S.p.A (STVN) Italy $6.726B 41.13
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $6.153B 0.00
Madrigal Pharmaceuticals (MDGL) United States $6.112B 0.00
Grifols, S.A (GRFS) Spain $5.714B 0.00
Ionis Pharmaceuticals (IONS) United States $5.333B 0.00
Ono Pharmaceutical (OPHLF) Japan $4.875B 14.83
Soleno Therapeutics (SLNO) United States $3.696B 0.00
Crinetics Pharmaceuticals (CRNX) United States $2.857B 0.00
Hypermarcas (HYPMY) Brazil $2.812B 18.50
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $2.294B 12.41
BioCryst Pharmaceuticals (BCRX) United States $2.249B 0.00
NewAmsterdam Pharma (NAMS) Netherlands $2.033B 0.00
Centessa Pharmaceuticals (CNTA) United Kingdom $1.804B 0.00
Indivior (INDV) United States $1.773B 7.52
Recursion Pharmaceuticals (RXRX) United States $1.699B 0.00
ARS Pharmaceuticals (SPRY) United States $1.417B 0.00
Evotec AG (EVO) Germany $1.410B 0.00
Dyne Therapeutics (DYN) United States $1.359B 0.00
Guardian Pharmacy Services (GRDN) United States $1.340B 0.00
Ocular Therapeutix (OCUL) United States $1.276B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.059B 21.19
Harrow (HROW) United States $1.031B 0.00
Collegium Pharmaceutical (COLL) United States $0.936B 5.05
Avadel Pharmaceuticals (AVDL) Ireland $0.881B 0.00
Ardelyx (ARDX) United States $0.878B 0.00
Enliven Therapeutics (ELVN) United States $0.872B 0.00
Akebia Therapeutics (AKBA) United States $0.796B 0.00
Xeris Biopharma Holdings (XERS) United States $0.773B 0.00
Cronos Group (CRON) Canada $0.763B 0.00
AleAnna (ANNA) United States $0.624B 0.00
KalVista Pharmaceuticals (KALV) United States $0.587B 0.00
Elite Pharmaceuticals (ELTP) United States $0.577B 0.00
Xencor (XNCR) United States $0.569B 0.00
USANA Health Sciences (USNA) United States $0.556B 12.09
Regulus Therapeutics (RGLS) United States $0.549B 0.00
Bioventus (BVS) United States $0.532B 13.50
Relay Therapeutics (RLAY) United States $0.514B 0.00
Zevra Therapeutics (ZVRA) United States $0.468B 0.00
Amylyx Pharmaceuticals (AMLX) United States $0.459B 0.00
Theravance Biopharma (TBPH) Cayman Islands $0.458B 0.00
Altimmune (ALT) United States $0.440B 0.00
Tourmaline Bio (TRML) United States $0.428B 0.00
Siga Technologies (SIGA) United States $0.427B 8.93
CytoDyn (CYDY) United States $0.427B 0.00
Oruka Therapeutics (ORKA) United States $0.410B 0.00
Verve Therapeutics (VERV) United States $0.397B 0.00
Savara (SVRA) United States $0.394B 0.00
Organogenesis (ORGO) United States $0.348B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.343B 9.28
Tonix Pharmaceuticals Holding (TNXP) United States $0.291B 0.00
Heron Therapeutics (HRTX) United States $0.287B 0.00
Nature's Sunshine Products (NATR) United States $0.284B 26.20
Aquestive Therapeutics (AQST) United States $0.269B 0.00
MediWound (MDWD) Israel $0.237B 0.00
ProKidney (PROK) United States $0.212B 0.00
Nanobiotix S.A (NBTX) France $0.193B 0.00
Journey Medical (DERM) United States $0.188B 0.00
Esperion Therapeutics (ESPR) United States $0.168B 0.00
4D Molecular Therapeutics (FDMT) United States $0.168B 0.00
Profound Medical (PROF) Canada $0.158B 0.00
Aclaris Therapeutics (ACRS) United States $0.158B 0.00
OmniAb (OABI) United States $0.155B 0.00
Inhibikase Therapeutics (IKT) United States $0.149B 0.00
Avita Medical (RCEL) United States $0.149B 0.00
Wellgistics Health (WGRX) United States $0.144B 0.00
Larimar Therapeutics (LRMR) United States $0.144B 0.00
Liminatus Pharma (LIMN) $0.141B 0.00
Nektar Therapeutics (NKTR) United States $0.135B 0.00
Lyell Immunopharma (LYEL) United States $0.129B 0.00
Aldeyra Therapeutics (ALDX) United States $0.129B 0.00
Enanta Pharmaceuticals (ENTA) United States $0.127B 0.00
Achieve Life Sciences (ACHV) Canada $0.124B 0.00
Innate Pharma SA (IPHYF) France $0.122B 0.00
Protara Therapeutics (TARA) United States $0.117B 0.00
Korro Bio (KRRO) United States $0.107B 0.00
Cardiol Therapeutics (CRDL) Canada $0.103B 0.00
VAXART, INC (VXRT) United States $0.099B 0.00
OptiNose (OPTN) United States $0.097B 0.00
Cassava Sciences (SAVA) United States $0.097B 0.00
Ironwood Pharmaceuticals (IRWD) United States $0.097B 0.00
Fractyl Health (GUTS) United States $0.093B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.091B 0.00
Lexeo Therapeutics (LXEO) United States $0.090B 0.00
Inotiv (NOTV) United States $0.089B 0.00
Arch Biopartners (ACHFF) Canada $0.085B 0.00
Galectin Therapeutics (GALT) United States $0.083B 0.00
Champions Oncology (CSBR) United States $0.081B 13.34
Pyxis Oncology (PYXS) United States $0.075B 0.00
Vivani Medical (VANI) United States $0.075B 0.00
ESSA Pharma (EPIX) Canada $0.075B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.074B 55.11
Surrozen (SRZN) United States $0.073B 0.00
Nutriband (NTRB) United States $0.073B 0.00
Unicycive Therapeutics (UNCY) United States $0.071B 0.00
Dominari Holdings (DOMH) United States $0.065B 0.00
Assertio Holdings (ASRT) United States $0.064B 0.00
Metagenomi (MGX) United States $0.064B 0.00
Allergy Therapeutics (AGYTF) United Kingdom $0.059B 0.00
Telomir Pharmaceuticals (TELO) United States $0.058B 0.00
Gain Therapeutics (GANX) United States $0.053B 0.00
Context Therapeutics (CNTX) United States $0.052B 0.00
Prelude Therapeutics (PRLD) United States $0.050B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.046B 0.00
Century Therapeutics (IPSC) United States $0.046B 0.00
NRx Pharmaceuticals (NRXP) United States $0.046B 0.00
PMV Pharmaceuticals (PMVP) United States $0.046B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.045B 0.00
Mural Oncology (MURA) Ireland $0.045B 0.00
Avalo Therapeutics (AVTX) United States $0.043B 0.00
Iterum Therapeutics (ITRM) Ireland $0.040B 0.00
ElectroCore (ECOR) United States $0.037B 0.00
Karyopharm Therapeutics (KPTI) United States $0.036B 0.00
Rafael Holdings (RFL) United States $0.036B 0.00
SCYNEXIS (SCYX) United States $0.034B 0.00
Acrivon Therapeutics (ACRV) United States $0.033B 0.00
FibroGen (FGEN) United States $0.029B 0.00
PolyPid (PYPD) Israel $0.029B 0.00
Jupiter Neurosciences (JUNS) United States $0.026B 0.00
Relmada Therapeutics (RLMD) United States $0.025B 0.00
CASI Pharmaceuticals (CASI) China $0.023B 0.00
Enlivex Therapeutics (ENLV) Israel $0.022B 0.00
China SXT Pharmaceuticals (SXTC) China $0.022B 0.00
Tempest Therapeutics (TPST) United States $0.022B 0.00
Natural Alternatives (NAII) United States $0.021B 0.00
BioVie (BIVI) United States $0.019B 0.00
Mannatech (MTEX) United States $0.019B 0.00
Lipocine (LPCN) United States $0.018B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.018B 0.00
BioLineRx (BLRX) Israel $0.017B 0.00
TherapeuticsMD (TXMD) United States $0.017B 0.00
DURECT (DRRX) United States $0.016B 0.00
ProPhase Labs (PRPH) United States $0.015B 0.00
VYNE Therapeutics (VYNE) United States $0.014B 0.00
Vivos Therapeutics (VVOS) United States $0.014B 0.00
Ainos (AIMD) United States $0.014B 0.00
Ernexa Therapeutics (ERNA) United States $0.014B 0.00
GlycoMimetics (GLYC) United States $0.014B 0.00
Cosmos Health (COSM) United States $0.013B 0.00
Scienture Holdings (SCNX) United States $0.011B 0.00
Mangoceuticals (MGRX) United States $0.011B 0.00
Minerva Neurosciences (NERV) United States $0.011B 1.88
Talphera (TLPH) United States $0.010B 0.00
Phio Pharmaceuticals (PHIO) United States $0.010B 0.00
SHINECO (SISI) China $0.009B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.009B 0.00
Addex Therapeutics (ADXN) Switzerland $0.009B 0.00
Carisma Therapeutics (CARM) United States $0.008B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.008B 0.00
Traws Pharma (TRAW) United States $0.008B 0.00
Biomerica (BMRA) United States $0.008B 0.00
Nuvilex (PMCB) United States $0.007B 0.00
Citius Pharmaceuticals (CTXR) United States $0.007B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.007B 0.00
Lyra Therapeutics (LYRA) United States $0.007B 0.00
Incannex Healthcare (IXHL) Australia $0.006B 0.00
Klotho Neurosciences (KLTO) United States $0.006B 0.00
TransCode Therapeutics (RNAZ) United States $0.006B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.006B 0.00
Indaptus Therapeutics (INDP) United States $0.005B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.005B 0.00
Aptorum Group (APM) United Kingdom $0.005B 0.00
Plus Therapeutics (PSTV) United States $0.005B 0.00
Xenetic Biosciences (XBIO) United States $0.005B 0.00
Clearmind Medicine (CMND) Canada $0.004B 0.00
Redhill Biopharma (RDHL) Israel $0.004B 0.00
Alaunos Therapeutics (TCRT) United States $0.004B 0.00
PainReform (PRFX) Israel $0.004B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.004B 0.00
XORTX Therapeutics (XRTX) Canada $0.004B 0.00
Heatwurx (PCSA) United States $0.003B 0.00
CERo Therapeutics Holdings (CERO) United States $0.003B 0.00
SciSparc (SPRC) Israel $0.003B 0.00
Aditxt (ADTX) United States $0.003B 0.00
InMed Pharmaceuticals (INM) Canada $0.003B 0.00
Jaguar Animal Health (JAGX) United States $0.003B 0.00
Qualigen Therapeutics (QLGN) United States $0.003B 0.00
Conduit Pharmaceuticals (CDT) United States $0.003B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.002B 0.00
TNF Pharmaceuticals (TNFA) United States $0.002B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.002B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.002B 0.00
Universe Pharmaceuticals INC (UPC) China $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
MEI Pharma (MEIP) United States $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00
Silence Therapeutics (SLN) United Kingdom $0.000B 0.00